CGRP (8-37) (mouse, rat) (trifluoroacetate salt)
(Synonyms: Calcitonin Gene-Related Peptide (8-37), CGRP8-37, VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH2) 目录号 : GC52438A CGRP receptor antagonist
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Calcitonin gene-related protein (CGRP) (8-37) is a CGRP receptor antagonist.1 It corresponds to amino acids 8-37 of rodent α-CGRP , a neuropeptide. CGRP (8-37) selectively binds to heterotrimeric complexes of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein 1 (RAMP1) or RAMP3 (IC50s = 1 and 6.2 nM, respectively) over a complex of CRLR and RAMP2 (IC50 = 219 nM). It prevents CGRP-induced increases in heart rate and decreases in blood pressure in transgenic mice expressing rat CRLR in smooth muscle-containing tissues and sympathetic ganglia when administered at a dose of 2 µmol/kg.2 CGRP (8-37) also inhibits p-phenylquinone-induced writhing (ED50 = 6 µg/animal) and decreases body temperature in a dose-dependent manner in mice.3
1.Husmann, K., Born, W., Fischer, J.A., et al.Three receptor-activity-modifying proteins define calcitonin gene-related peptide or adrenomedullin selectivity of the mouse calcitonin-like receptor in COS-7 cellsBiochem. Pharmacol.66(11)2107-2115(2003) 2.Kunz, T.H., Scott, M., Ittner, L.M., et al.Calcitonin gene-related peptide-evoked sustained tachycardia in calcitonin receptor-like receptor transgenic mice is mediated by sympathetic activityAm. J. Physiol. Heart Circ. Physiol.293(4)H2155-H2160(2007) 3.Saxen, M.A., Smith, F.L., Dunlow, L.D., et al.The hypothermic and antinociceptive effects of intrathecal injection of CGRP (8-37) in miceLife Sci.55(21)1665-1674(1994)
Cas No. | SDF | Download SDF | |
别名 | Calcitonin Gene-Related Peptide (8-37), CGRP8-37, VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH2 | ||
Canonical SMILES | OC(C(F)(F)F)=O.CC(C)[C@H](N[H])C(N[C@]([C@H](O)C)([H])C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN[H])C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C(C)C)C(N2CCC[C@H]2C(N[C@]([C@H](O)C)([H])C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(N)=O)CC3=CC=CC=C3)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC(C)C)=O)CC(C)C)=O)=O)C)=O)CC(C)C)=O)=O)=O)=O | ||
分子式 | C138H224N42O41 ? XCF3COOH | 分子量 | 3127.5 |
溶解度 | PBS (pH 7.2): 2 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.3197 mL | 1.5987 mL | 3.1974 mL |
5 mM | 0.0639 mL | 0.3197 mL | 0.6395 mL |
10 mM | 0.032 mL | 0.1599 mL | 0.3197 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。